February 28, 2020 / 12:17 PM / a month ago

BRIEF-Mereo Biopharma Says Have A Clear Path Forward To Initiate Late-Stage Study Of Setrusumab

Feb 28 (Reuters) - Mereo BioPharma Group plc:

* MEREO BIOPHARMA ANNOUNCES POSITIVE FEEDBACK FROM TYPE B END-OF-PHASE 2 MEETING WITH THE FDA AND OUTLINES PIVOTAL PHASE 3 PEDIATRIC STUDY DESIGN FOR SETRUSUMAB IN OSTEOGENESIS IMPERFECTA

* MEREO BIOPHARMA GROUP - HAVE A CLEAR PATH FORWARD TO INITIATE A PHASE 3 STUDY OF SETRUSUMAB IN PEDIATRIC OI Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below